A Phase 1b/2 Study of Idelalisib in Combination with BI 836826 in Subjects with Chronic Lymphocytic Leukemia
A study for patients Chronic Lymphocytic Leukemia using study drug BI 836826
Sponsor: Gilead Sciences, Inc
Enrolling: Male and Female Patients
IRB Number: AAAQ4712
U.S. Govt. ID: NCT02538614
Contact: Nicole Lamanna: 646-317-5077 / nl2129@cumc.columbia.edu
Additional Study Information: The purpose of the study is to see if a combination of idelalisib and BI 836826 can help control patients with Chronic Lymphocytic Leukemia (CLL) without serious side effects.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Nicole Lamanna
nl2129@cumc.columbia.edu
646-317-5077
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE